Development and validation of first and zero order derivative spectrophotometric methods for the determination of rilmenidine in pharmaceutical preparations and forced degradation study

Zero and first order derivative spectrophotometric methods were developed for the analysis of rilmenidine in pharmaceutical preparations. Absorbances of rilmenidine were measured at 224 nm for the zero order by measuring height of peak from zero and at 223.20 and 230.20 nm for the first order derivative spectrophotometric method by measuring peak to peak height. The linearity ranges were found to be 50-250 μg/mL for zero and first order spectrophotometric method. The developed methods were validated and the analytical parameters of linearity, limit of detection, limit of quantification, accuracy, precision and recovery were evaluated. In addition, Rilmenidine exposed to the stress conditions of acid, base and oxidative in order to calculate to degradation % by developed zero and first order derivative spectrophotometric method.

PDF

___

[1] Head GA, Chatzivlastou K, Lukoshkova EV, Jennings GL, Reid CM. A novel measure of the power of the morning blood pressure surge from ambulatory blood pressure recordings. Am J Hypertens. 2010; 23(10): 1074–1081. [CrossRef
[2] Head GA, Reid CM, Shiel LM, Jennings GL, Lukoshkova EV. Rate of morning rise in blood pressure is elevated in hypertensives. Am J Hypertens. 2006; 19(10): 1010–1017. [CrossRef]
[3] Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006; 29 (8): 581–587. [CrossRef]
[4] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365 (9455): 217–223.
[5] Writing Group Members, Mozaffarian D, Benjamin Ej, et al. Executive summary: heart disease and stroke statistics– 2016 update: A report from the American heart association. Circulation. 2016; 133(4): 447–454. [CrossRef]
[6] Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide pre-valence of hypertension: a systematic review. J Hypertens. 2004; 22: 11–19.
[7] Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub- Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016; 11: 299–305. [CrossRef]
[8] Mohammed NM, Sher Abdo HR, Hassan HM. Method development and valıdatıon of sımultaneous determınatıon of hydrochlorothıazıde and losartan ın tablet dosage form by RP-HPLC. Int J Pharm Sci & Res. 2019; 10(1): 227-231. [CrossRef]
[9] Mahrouse MA. Simultaneous ultraperformance liquid chromatography/tandem mass spectrometry determination of four antihypertensive drugs in human plasma using hydrophilic-lipophilic balanced reversed-phase sorbents sample preparation protocol. Biomed Chromatogr. 2018; 32(12): e4362. [CrossRef]
[10] Magdy R, El-Khatib AH, Hemdan A, Elaziz QA, Farouk M, Linscheid MW. Comparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC-MS/MS. Drug Test Anal. 2018; 10(7): 1158-1167. [CrossRef]
[11] Babarahimi V, Talebpour Z, Haghighi F, Adib N, Vahidi H.Validated determination of losartan and valsartan in human plasma by stir bar sorptive extraction based on acrylate monolithic polymer, liquid chromatographic analysis and experimental design methodology. J Pharm Biomed Anal. 2018; 153: 204-213. [CrossRef]
[12] Santala EE, Rannikko A, Murtola TJ.Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 2019; 144(3): 440-447. [CrossRef]
[13] Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000; 13(6 Pt 2): 106S-111S. [CrossRef]
[14] PubChem, Open Chemistry Database. http://pubchem.ncbi.nlm.nih.gov (Accessed: January 4, 2019).
[15] Sweetman SC (ed.). Martindale: The Extra Pharmacopoeia, pp. 996, 34th edition. London: The Pharmaceutical Press; 2005.
[16] Servier. Summary of product characteristics: Hyperium. http://www.servier.com. (Accessed:January 31, 2019).
[17] Chytil L, Cvačka J, Marešová V, Štrauch B, Widimský J, Štícha JM, Slanař O. Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. J Mass Spec. 2010; 45: 1179-1185. [CrossRef]
[18] Ambadas RR, Swapnil RB. First-order derivative spectrophotometric estimation of nabumetone and paracetamol in tablet dosage form. Pharm Methods. 2011; 2(4): 260-263. [CrossRef]
[19] Ojeda CB, Rojas FS. Recent developments in derivative ultraviolet/visible absorption spectrophotometry. Anal Chim Acta. 2004; 518: 1-24. [CrossRef]
[20] International Conference on Harmonization, Stability Testing of New Drug Substances and Products, in: International Conference on Harmonization, 1993.
[21] Rojas FS, Ojeda CB, Pavon JM. Derivative ultraviolet—visible region absorption spectrophotometry and its analytical applications. Talanta. 1988; 35: 753-761. [CrossRef]
[22] Karpińska J. Derivative spectrophotometry—recent applications and directions of developments. Talanta. 2004; 64: 801-822. [CrossRef]
[23] Shirkhedkar AA, Bhirud HC, Surana JS. Application of UV-spectrophotometric methods for estimation of tenofovir disoproxil fumarate in tablets. Pak J Pharm Sci. 2009; 22: 27-29.
[24] Jenee C, Purvi S, Margi P, Kalpana P, Tejal G. Optimizing derivatization conditions using an experimental design and simultaneous estimation of artemether and lumefantrine by ratio first order derivative spectrophotometric method. J Taibah Univ Sci. 2017; 11: 729-740. [CrossRef]
[25] Dimal AS, Dixita JS, Chirag ND, Usman KC, Kashyap KB, Estimation of ibuprofen and famotidine in tablets by second order derivative spectrophotometry method. Arab J Chem. 2017; 10: 105-108. [CrossRef]
[26] International Conference on Harmonization. ICH. Validation of analytical procedures: text and methodology Q2 R1. 2005.
[27] International Conference on Harmonization, ICH. Stability testing of new drug substances and products Q1A R2 2003.